Oxidative stress in COPD: Molecular background and clinical monitoring

Current Medicinal Chemistry

Volumn 22, Issue 5, 2015, Pages 627-650

  Antus, Balazs ^a   Kardos, Zsuzsanna ^a  

^a NATIONAL KORANYI INSTITUTE OF PULMONOLOGY   (Hungary)

Author keywords

Chronic obstructive pulmonary disease; Eicosanoids; Isofurans; Isoprostanes; Lipid peroxidation; Oxidative stres polyunsaturated fatty acids; Reactive oxygen and nitrogen species

Indexed keywords

3 NITROTYROSINE; 8 EPI PROSTAGLANDIN F 2ALPHA; 8 ISOPROSTANE; ALDEHYDE; ARACHIDONIC ACID; BIOLOGICAL MARKER; CARBON MONOXIDE; COPPER ZINC SUPEROXIDE DISMUTASE; ETHANE; FREE RADICAL; HYDROCARBON; HYDROGEN PEROXIDE; ICOSANOID; ICOSAPENTAENOIC ACID; ISOPROSTANE DERIVATIVE; LEUKOTRIENE; MALONALDEHYDE; NITROGEN OXIDE; OMEGA 6 FATTY ACID; OXYGEN; PENTANE; PEROXY RADICAL; PROSTANOID; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; REACTIVE NITROGEN SPECIES;

ARTICLE; BIOSYNTHESIS; CATALYSIS; CELL MEMBRANE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYCLIZATION; HUMAN; HUMAN CELL; HYDROXYLATION; LIPID PEROXIDATION; MOLECULAR WEIGHT; OXIDATIVE STRESS; PROTON TRANSPORT; BREATH ANALYSIS; PATHOPHYSIOLOGY; PHYSIOLOGY;

BREATH TESTS; HUMANS; LIPID PEROXIDATION; OXIDATIVE STRESS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN SPECIES;

EID: 84925405105     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986732205150112104411     Document Type: Article

References (156)

1. Mannino, D. M.; Buist, A. S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet, 2007, 370, 765-773.
2. Mathers, CD.; Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. Plos. Med., 2006, 3, e442.
3. Kirkham, PA.; Barnes, P. J. Oxidative stress in COPD. Chest, 2013, 144, 266-273.
4. Tuder, R. M.; Petrache, I. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Invest., 2012, 122, 2749-2755.
5. Barnes, P. J. Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease. J. Allergy. Clin. Immunol, 2013, 131, 636-645.
6. Barnes, P. J.; Chowdhury, B.; Kharitonov, S. A.; Magnussen, H.; Page, C. P.; Postma, D.; Saetta, M. Pulmonary biomarkers in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2006, 174, 6-14.
7. Loukides, S.; Bakakos, P.; Kostikas, K. Oxidative stress in patients with COPD. Curr. Drug Targets, 2011, 12, 469-477.
8. Koutsokera, A.; Kostikas, K; Nicod, L. P.; Fitting, J. W. Pulmonary biomarkers in COPD exacerbations: a systematic review. Respir. Res., 2013, 14, 111.
9. Malerba, M.; Montuschi, P. Non-invasive biomarkers of lung inflammation in smoking subjects. Curr. Med. Chem., 2012, 19, 187-196.
10. Biswas, S.; Hwang, J. W.; Kirkham, PA.; Rahman I. Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease. Curr. Med. Chem., 2013, 20, 1496-1530.
11. Niki. E. Lipid peroxidation: Physiological levels and dual biological effects. Free Radical Biol. Chem., 2009, 47, 469-484.
12. Yin, H.; Xu, L.; Porter, NA. Free radical lipid peroxidation: mechanisms and analysis. Chem. Rev., 2011, 111, 5944-5972.
13. Antus, B. Pharmacotherapy of chronic obstructive pulmonary disease a clinical review. ISRN Pulmonol. 2013, 2013, ID582807.
14. Kehrer, J. P. The Haber-Weiss reaction and mechanism of toxicity. Toxycology, 2000, 149, 43-50.
15. Fenton, HJ. R. Catalytic decomposition of hydrogen peroxide presence of iron. J. Chem. Soc, 1894, 65, 890-910.
16. Moncada, S.; Higgs, E. A. Endogenous nitric oxide: Physiology, pathology and clinical relevance. Eur. J. Clin. Invest., 1991, 21, 361-374.
17. Church, D. F.; Pryor, W. A. Free radical chemistry of cigarette smoke and its toxicological implications. Environ. Health Perspect, 1985, 64, 111-126.
18. Rahman, I.; MacNee, W. Antioxidant pharmacological therapies for COPD. Curr. Opin. Pharmacol., 2012, 12, 256-265.
19. Blair, I. A. Lipid-hydroperoxide-mediated DNA damage. Exp. Gerontol., 2004, 36, 1473-1481.
20. Tappel, A. L. Lipid peroxidation damage to cell components. Fed. Proc., 1973, 32, 1870-1874.
21. He, J.; Turino, G. M.; Lin, Y. Y. Characterization of peptide fragments from lung elastin degradation in chronic obstructive pulmonary disease. Exp. Lung Res., 2010, 36, 548-557.
22. Cao, Y.; Cao, Y.; Zhao, M. Biotechnological production of eicosapentaenoic acid: From a metabolic engineering point of view. Process Biochem., 2012, 47, 1320-1326.
23. Bogatcheva, N. V.; Seergeva, M. G.; Dudek, S. M.; Verin, A. D. Arachidonic acid cascade in endothelial pathobiology. Microvascu. Res., 2005, 69, 107-127.
24. Milne, G. L.; Yin, H.; Morrow, J. D. Human biochemistry of the isoprostanes pathway. J. Biol. Chem., 2008, 283, 15533-15537.
25. Arreaza, G.; Devane, W. A.; Omeir, R.l.; Sajnani, G.; Kunz, J.; Cravatt B. F.; Deutsch, D. G. The cloned rat hydrolytic enzyme responsible for the breakdown of anandamide also catalyses its formation via the condensation of arachidonic acid and ethanolamide. Neurosci. Lett., 1977, 234, 59-62.
26. Morrow, J. D.; Hill, K. E.; Burk, R. F.; Nammour, T. M.; Badr, K. F.; Roberts, L. J. A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radicalcatalyzed mechanism. Proc. Natl. Acad. Sci. USA, 1990, 87, 9383-9387.
27. Morrow, J. D.; Award, J. A.; Boss, H. J.; Blair, I. A; Roberts, L. J. Non-cycloxygenase-derived prostanoids (F2-isoprostanes) are formed in situ on phospholipids. Proc. Natl. Acad. Sci. USA, 1992, 89, 10721-10725.
28. Ingold, K. U. Peroxy Radicals. Acc. Chem. Res., 1969, 2, 1-9.
29. Barclay, L. R. C.; Ingold, K. U. Autoxidation of a model membrane. A comparison of the autoxidation of egg lecichtin phosphatidylcholine in water and in chlorobenzene. J. Am. Chem. Soc., 1980, 102, 7792-7794.
30. Barclay, L. R. C.; Baskin, K. A.; Dakin, K. A.; Locke, S. J. Vinqvist, M. R. The antioxidant activities of phenolic antioxidants in free radical peroxidation of phospholipids membranes. Can. J. Chem., 1990, 68, 2258-2269.
31. Pratt, D. A.; Mills, J. H.; Porter, N. A. Theoretical calculations of carbon-oxygen bond dissociation enthalpies of peroxyl radicals formed in the autoxidation of lipids. J. Am. Chem. Soc., 2003, 125, 5801-5810.
32. Howard, J. A. In Advances in Free Radical Chemistry. G. H. Williams, Ed.; Logos Press London Vol. IV, 1972, p. 49.
33. Eliel, E. L. Recent advances in stereochemical nomenclature J. Chem. Educ., 1971, 48, 163-167
34. Davies, K. J. Oxidative stress, antioxidant defenses, and damage; Removal, repair, and replacement systems. IUBMB. Life, 2000, 50, 279-289.
35. Morrow, J. D.; Harris, T. M.; Roberts Jr., J. L. Non-cyclooxygenase oxidative formation of series of novel prostaglandins-analytical ramifications for measurement of eicosanoids. Anal. Biochem., 1990, 184, 1-10.
36. Morrow, J. D.; Roberts, L. J. 2nd. The isoprostanes. Current knowledge and directions for future research. Biochem. Pharmacol., 1996, 51, 1-9.
37. Beckwith, A. L. J.; Schiesser, C. H. Regio- and stereo-selectivity of alkenyl radical ring closure: A theoretical study. Tetrahedron, 1985, 41, 3925-3941.
38. Spellmeyer, D.; Houck, K. Force-field model for intramolecular radical additions. J. Org. Chem., 1987, 52, 959-974.
39. O'Connor, D. E.; Mihelich, E. D.; Coleman, M. C. Stereochemical course of the autoxidative cyclization of lipid hydroperoxides to prostaglandin-like bicyclic endoperoxides. J. Am. Chem. Soc., 1984, 106, 3577-3584.
40. Corey, E. J.; Wang, Z. Conversion of arachidonic acid to the prostaglandin endoperoxide PGG2, a chemical analog of the biosynthetic pathway. Tetrahedron Lett., 1994, 35, 539-542.
41. Niki, E.; Yoshida, Y.; Saito, V.; Noguchy, N. Lipid peroxidation: Mechanisms, inhibition and biological effects. Biochem. Biophys. Res. Commun., 2005, 338, 668-676.
42. Tang, D. G.; La, E.; Kehrer, J. P. Fatty acid oxidation and signaling in apoptosis. Biol. Chem., 2002, 383, 425-442.
43. Porter, N. A.; Nixon, J. R. Stereochemistry of free-radical substitution on the peroxide bond. J. Am. Chem. Soc., 1978, 100, 7116-7117.
44. Chatgilialoglu, C.; Ingold, K. U.; Scaiano, C. J. Rate constants and Arrhenius parameters for the reactions of primary, secondary, and tertiary alkyl radicals with tri-n-butyltin hydride. J. Am. Chem. Soc., 1981, 103, 7739-7742.
45. Fessel, J. P.; Jackson Roberts, L. Isofurans: Novel products of lipid peroxidation that define the occurrence of oxidant injury in settings of elevated oxygen tension. Antioxid. Redox Signal., 2005, 7, 202-209.
46. Yin, H.; Havrilla, C. M.; Morrow, J. D.; Porter, N. A. Formation of isoprostane bicyclic endoperoxides from the autoxidation of cholesterol arachidonate. J. Am. Chem. Soc., 2002, 124, 7745-7754.
47. Spector, A. A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res., 2009, 50, S52-S56.
48. Liu, W.; Porter, N. A.; Schneider, C.; Brash, A. R.; Yin, H. Formation of 4-hydroxynonenal from cardiolipin oxidation: Intramolecular peroxyl radical addition and decomposition. Free Radical Biol. Med., 2011, 50, 166-178.
49. Yu, Z.; Xu, F.; Huse, L. M.; Morisseau, C.; Draper, A. J.; Newman, J. W.; Parker, C.; Graham, L.; Engler, M. M.; Hammock, B. D.; Zeldin, D. C.; Kroetz, D. L. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoc acids. Circ. Res., 2000, 87, 992-998.
50. Capdevila, J. H.; Falck, J. R. Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat., 2002, 68-69, 325-344.
51. Smith, W. L.; Urade, Y.; Jakobsson, P. J. Enzymes of the cyclooxygenase pathway of prostanoid biosynthesis. Chem. Rev., 2011, 111, 5821-5865.
52. Rouzer, C. A.; Marnett, L. J. Cyclooxygenase: structural and functional insights. J. Lipid. Res., 2009, 50, S29-S34.
53. Samuelsson, B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science, 1983, 220, 568-575.
54. Barnes, P. J. Mediators of chronic obstructive pulmonary disease. Pharmacol. Rev., 2004, 56, 515-548.
55. Lundström, S. L.; Balgoma, D.; Wheelock, Å. M.; Haeggström, J. Z.; Dahlén, S. E.; Wheelock, C. E. Lipid mediator profiling in pulmonary disease. Curr. Pharm. Biotechnol., 2011, 12, 1026-1052.
56. Borrill, Z. L.; Starkey, R. C.; Singh, S. D. Variability of exhaled breath condensate leukotriene B4 and 8-isoprostane in COPD patients. Int. J. Chron. Obstruct. Pulmon. Dis., 2007, 2, 71-76.
57. Franklin, P.; Moeller, A.; Hall, G. L.; Horak, F. Jr.; Patterson, H., Stick, S. M. Variability of nitric oxide metabolites in exhaled breath condensate. Respir. Med., 2006, 100, 123-129.
58. Corhay, J. L.; Henket, M.; Nguyen, D.; Duysinx, B.; Sele, J.; Louis, R. Leukotriene B4 contributes to exhaled breath condensate and sputum neutrophil chemotaxis in COPD. Chest, 2009, 136, 1047-1054.
59. Warwick, G.; Thomas, P. S.; Yates, D. H. Non-invasive biomarkers in exacerbation of obstructive lung disease. Respirology, 2013, 18, 874-884.
60. Bathoorn, E.; Liesker, J. J.; Postma, D. S.; Koëter, G. H.; Van Der Toorn, M.; Van Der Heide, S.; Ross, H. A.; Van Oosterhout, A. J.; Kerstjens, H. A. Change in inflammation in out-patient COPD patients from stable phase to a subsequent exacerbation. Int. J. Chron. Obstruct. Pulmon. Dis., 2009, 4, 101-109.
61. Crooks, S. W.; Bayley, D. L.; Hill, S. L.; Stockley, R. A. Bronchial inflammation in acute bacterial exacerbations of chronic bronchitis: the role of leukotriene B4. Eur. Respir. J., 2000, 15, 274-280.
62. Björk, J.; Hedqvist, P.; Arfors, K. E. Increase in vascular permeability induced by leukotriene B4 and the role of polymorphonuclear leukocytes. Inflammation, 1982, 6, 189-200.
63. Dahlén, S. E.; Björk, J.; Hedqvist, P.; Arfors, K. E.; Hammarström, S.; Lindgren, J. A.; Samuelsson, B. Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. Proc. Natl. Acad. Sci. USA., 1981, 78, 3887-3891.
64. Ott, V. L.; Cambier, J. C.; Kappler, J.; Marrack, P.; Swanson, B. J. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat. Immunol., 2003, 4, 974-981.
65. Sakata, K.; Dahlén, S. E.; Bäck, M. The contractile action of leukotriene B4 in the guinea-pig lung involves a vascular component. Br. J. Pharmacol., 2004, 141, 449-456.
66. Busse, W. W. Leukotrienes and inflammation. Am. J. Respir. Crit. Care. Med., 1998, 157, S210-S213.
67. Profita, M.; Giorgi, R. D.; Sala, A.; Bonanno, A.; Riccobono, L.; Mirabella, F.; Gjomarkaj, M.; Bonsignore, G.; Bousquet, J.; Vignola, A. M. Muscarinic receptors, leukotriene B4 production and neutrophilic inflammation in COPD patients. Allergy, 2005, 60, 1361-1369.
68. Kostikas, K.; Gaga, M.; Papatheodorou, G.; Karamanis, T.; Orphanidou, D.; Loukides, S. Leukotriene B4 in exhaled breath condensate and sputum supernatant in patients with COPD and asthma. Chest, 2005, 127, 1553-1559.
69. Biernacki, W. A.; Kharitonov, S. A.; Barnes, P. J. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax, 2003, 58, 294-298.
70. Seggev, J. S.; Thornton, W. H. Jr.; Edes, T. E. Serum leukotriene B4 levels in patients with obstructive pulmonary disease. Chest, 1991, 99, 289-291.
71. Montuschi, P.; Kharitonov, S. A.; Ciabattoni, G.; Barnes, P. J. Exhaled leukotrienes and prostaglandins in COPD. Thorax, 2003, 58, 585-588.
72. Gaber, F.; Acevedo, F.; Delin, I.; Sundblad, B. M.; Palmberg, L.; Larsson, K.; Kumlin, M.; Dahlén, S. E. Saliva is one likely source of leukotriene B4 in exhaled breath condensate. Eur. Respir. J., 2006, 28, 1229-1235.
73. Borrill, Z. L.; Roy, K.; Singh, D. Exhaled breath condensate biomarkers in COPD. Eur. Respir. J., 2008, 32, 472-486.
74. Czebe, K.; Barta, I.; Antus, B.; Valyon, M.; Horváth, I.; Kullmann, T. Influence of condensing equipment and temperature on exhaled breath condensate pH, total protein and leukotriene concentrations. Respir. Med., 2008, 102, 720-725.
75. Drozdovszky, O.; Barta, I.; Antus, B. Sputum eicosanoid profiling in exacerbations of chronic obstructive pulmonary disease. Respiration, 2014, 87, 408-415.
76. Laidlaw, T. M.; Boyce, J. A. Cysteinyl leukotriene receptors, old and new; implications for asthma. Clin. Exp. Allergy., 2012, 42, 1313-1320.
77. Pavord, I. D.; Tattersfield, A. E. Bronchoprotective role for endogenous prostaglandin E2. Lancet, 1995, 345, 436-438.
78. Bikov, A.; Gajdócsi, R.; Huszár, É.; Szili, B.; Lázár, Z.; Antus, B.; Losonczy, G.; Horváth, I. Exercise increases exhaled breath condensate cysteinyl leukotriene concentration in asthmatic patients. J. Asthma., 2010, 47, 1057-1062.
79. Birring, S. S.; Parker, D.; Brightling, C. E.; Bradding, P.; Wardlaw, A. J.; Pavord, I. D. Induced sputum inflammatory mediator concentrations in chronic cough. Am. J. Respir. Crit. Care. Med., 2004, 169, 15-19.
80. Antczak, A.; Ciebiada, M.; Pietras, T.; Piotrowski, W. J.; Kurmanowska, Z.; Górski, P. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Arch. Med. Sci., 2012, 8, 277-285.
81. Zhu, J.; Bandi, V.; Qiu, S.; Figueroa, D. J.; Evans, J. F.; Barnes, N.; Guntupalli, K. K.; Jeffery, P. K. Cysteinyl leukotriene 1 receptor expression associated with bronchial inflammation in severe exacerbations of COPD. Chest, 2012, 142, 347-357.
82. Drakatos, P.; Lykouras, D.; Sampsonas, F.; Karkoulias, K.; Spiropoulos, K. Targeting leukotrienes for the treatment of COPD? Inflamm. Allergy. Drug. Targets., 2009, 8, 297-306.
83. Montuschi, P.; Macagno, F.; Parente, P.; Valente, S.; Lauriola, L.; Ciappi, G.; Kharitonov, S. A.; Barnes, P. J.; Ciabattoni, G. Effects of cyclooxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax, 2005, 60, 827-833.
84. Profita, M.; Sala, A.; Bonanno, A.; Riccobono, L.; Ferraro, M.; La Grutta, S.; Albano, G. D.; Montalbano, A. M.; Gjomarkaj, M. Chronic obstructive pulmonary disease and neutrophil infiltration: role of cigarette smoke and cyclooxygenase products. Am. J. Physiol. Lung. Cell. Mol. Physiol., 2010, 298, L261-L269.
85. Chen, Y.; Chen, P.; Hanaoka, M.; Droma, Y.; Kubo, K. Enhanced levels of prostaglandin E2 and matrix metalloproteinase-2 correlate with the severity of airflow limitation in stable COPD. Respirology, 2008, 13, 1014-1021.
86. Louhelainen, N.; Myllärniemi, M.; Rahman, I.; Kinnula, V. L. Airway biomarkers of the oxidant burden in asthma and chronic obstructive pulmonary disease: current and future perspectives. Int. J. Chron. Obstruct. Pulmon. Dis., 2008, 3, 585-603.
87. Kubáň, P.; Foret, F. Exhaled breath condensate: determination of non-volatile compounds and their potential for clinical diagnosis and monitoring. A review. Anal. Chim. Acta., 2013, 805, 1-18.
88. Wood, L. G.; Gibson, P. G.; Garg, M. L. Biomarkers of lipid peroxidation, airway inflammation and asthma. Eur. Respir. J., 2003, 21, 177-186.
89. Montuschi, P.; Collins, J. V.; Ciabattoni, G.; Lazzeri, N.; Corradi, M.; Kharitonov, S. A.; Barnes, P. J. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. Am. J. Respir. Crit. Care. Med., 2000, 162, 1175-1177.
90. Kinnula, V. L.; Ilumets, H.; Myllärniemi, M.; Sovijärvi, A.; Rytilä, P. 8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. Eur. Respir. J., 2007, 29, 51-55.
91. Carpagnano, G. E.; Resta, O.; Foschino-Barbaro, M. P.; Spanevello, A.; Stefano, A.; Di Gioia, G; Serviddio, G.; Gramiccioni, E. Exhaled Interleukine-6 and 8-isoprostane in chronic obstructive pulmonary disease: effect of carbocysteine lysine salt monohydrate (SCMC-Lys). Eur. J. Pharmacol, 2004, 505, 169-175.
92. Dekhuijzen, P. N.; Aben, K. K.; Dekker, I.; Aarts, L. P.; Wielders, P. L.; Van Herwaarden, C. L.; Bast, A. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care. Med., 1996, 154, 813-816.
93. Koczulla, A. R.; Noeske, S.; Herr, C; Koepke, J.; Jörres, R. A.; Nell, C; Schmid, S.; Vogelmeier, C; Bals, R. Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients. Respir. Med., 2012, 106, 120-126.
94. Mohan, A.; Prasad, D.; Sharma, A.; Arora, S.; Guleria, R.; Sharma, S. K.; Pandey, R. M. Delayed resolution of inflammatory response compared with clinical recovery in patients with acute exacerbations of chronic obstructive pulmonary disease. Respirology, 2012, 17, 1080-1085.
95. Antus, B.; Horváth, I. Exhaled nitric oxide and carbon monoxide in respiratory diseases. J. Breath Res., 2007, 1, 024002.
96. Wolff, D. G.; Bidlack, W. R. The formation of carbon monoxide during peroxidation of microsomal lipids. Biochem. Biophys. Res. Commun., 1976, 4, 850-857.
97. Montuschi, P.; Kharitonov, S. A.; Barnes, P. J. Exhaled carbon monoxide and nitric oxide in COPD. Chest, 2001, 120, 496-501.
98. Carpagnano, G. E.; Kharitonov, S. A.; Foschino-Barbaro, M. P.; Resta, O.; Gramiccioni, E.; Barnes, P. J. Increased inflammatory markers in the exhaled breath condensate of cigarette smokers. Eur. Respir. J., 2003, 21, 589-593.
99. Deveci, S. E.; Deveci, F.; Aàšik, Y.; Ozan, A. T. The measurement of exhaled carbon monoxide in healthy smokers and non-smokers. Respir. Med., 2004, 98, 551-556.
100. Barta, I.; Drozdovszky, O.; Antus, B. Monitoring exhaled carbon monoxide in COPD exacerbations. Eur., Respir., J., 2014, 44, Suppl. 58, 999.
101. Ryter, S. W.; Choi, A. M. Carbon monoxide in exhaled breath testing and therapeutics. J. Breath. Res. 2013, 7, 0017111.
102. Zarling, E. J.; Clapper, M. Technique for gas-chromatographic measurement of volatile alkanes from single-breath samples. Clin. Chem., 1987, 33, 140-141.
103. Habib, M. P.; Clements, N. C.; Garewal, H. S. Cigarette smoking and ethane exhalation in humans. Am. J. Respir. Crit. Care Med., 1995, 151, 1368-1372.
104. Paredi, P.; Kharitonov, S. A.; Leak, D.; Ward, S.; Cramer, D.; Barnes, P. J. Exhaled ethane, a marker of lipid peroxidation, is elevated in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2000, 162, 369-373.
105. Pryor, W. A.; Stanley, J. P. A suggested mechanism for the production of malonaldehyde during the autoxidation of polyunsaturated fatty acids. Nonenzymatic production of prostaglandin endoperoxides during autoxidation. J. Org. Chem., 1975, 40, 3615-3617.
106. Esterbauer, H.; Schaur, R. J.; Zollner, H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free. Radic. Biol. Med, 1991, 11, 81-128.
107. McMillan, R. M.; MacIntyre, D. E.; Booth, A.; Gordon, J. L. Malonaldehyde formation in intact platelets catalysed by thromboxane synthase. Biochem. J., 1978, 176, 596-598.
108. Hecker, M.; Ullrich, V. On the mechanism of prostacyclin and thromboxane A2 biosynthesis. J. Biol. Chem., 1989, 264, 141-150.
109. Giera, M.; Lingeman, H.; Niessen, W. M. Recent advancements in the LC- and GC-based analysis of malondialdehyde (MDA): A brief overview. Chromatographia, 2012, 75, 433-440.
110. Lärstad, M.; Ljungkvist, G.; Olin, A. C.; Torén, K. Determination of malondialdehyde in breath condensate by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. B. Analyt. Technol. Biomed. Life. Sci., 2002, 766, 107-114.
111. Andreoli, R.; Manini, P.; Corradi, M.; Mutti, A.; Niessen, W. M. Determination of patterns of biologically relevant aldehydes in exhaled breath condensate of healthy subjects by liquid chromatography/atmospheric chemical ionization tandem mass spectrometry. Rapid Commun. Mass. Spectrom., 2003, 17, 637-645.
112. Corradi, M.; Rubinstein, I.; Andreoli, R.; Manini, P.; Caglieri, A.; Poli, D.; Alinovi, R.; Mutti, A. Aldehydes in exhaled breath condensate of patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2003, 167, 1380-1386.
113. Bartoli, M. L.; Novelli, F.; Costa, F.; Malagrinò, L.; Melosini, L.; Bacci, E.; Cianchetti, S.; Dente, F. L.; Di Franco, A.; Vagaggini, B.; Paggiaro, P. L. Malondialdehyde in exhaled breath condensate as a marker of oxidative stress in different pulmonary diseases. Mediators Inflamm., 2011, 2011, 891752.
114. Corradi, M.; Pignatti, P.; Manini, P.; Andreoli, R.; Goldoni, M.; Poppa, M.; Moscato, G.; Balbi, B.; Mutti, A. Comparison between exhaled and sputum oxidative stress biomarkers in chronic airway inflammation. Eur. Respir. J., 2004, 24, 1011-1017.
115. Antus, B.; Harnasi, G.; Drozdovszky, O.; Barta, I. Monitoring oxidative stress during COPD exacerbations using malondialdehyde. Respirology, 2014, 19, 74-79.
116. Crawford, D. L.; Yu, T. C.; Sinnbauer, R. O. Reaction of malondialdehyde with glycine. J. Agric. Food Chem., 1966, 14, 182-184.
117. Kikugawa, K.; Takayanagi, K.; Watanabe, S. Polylysines modified with malondialdehyde, hydroperoxylinoleic acid and monofunctional aldehyde. Chem. Pharm. Bull., 1985, 33, 5437-5444.
118. Draper, H. H; Hadley, M.; Lissemore, L.; Liang, N. M.; Cole, P. D. Identification of N-epsilon-(2-propenal) lysine as a major urinary metabolite of malondialdehyde. Lipids, 1988, 23, 626-628.
119. Chio, K. S.; Tappel, A. L. Synthesis and characterization of fluorescent products derived from malonaldehyde and amino acids. Products of malonaldehyde and amino acids. Biochemistry, 1969, 8, 2821-2832.
120. Seto, H.; Okuda, T.; Takesue, T.; Ikemura, T. Reaction of malondialdehyde with nucleic acid I. Formation of fluorescent pyrimidino (1, 2-a) purin10 (3H)-one nucleoside, Bull. Chem. Soc. Jap., 1983, 56, 1799-1802.
121. Marnett, J. L., Basu, A. K.; O'Hara, S. M.; Weller, P. E.; Rahman, A. F. M. M.; Oliver, J. P. Reaction of malondialdehyde with guanine nucleosides. Formation of adducts containing oxadiazabicyclononene residues in the base pairing region. J. Am. Chem. Soc., 1986, 108, 1348-1350.
122. Esterbauer, H.; Zollner, H.; Scholz, N. Reaction of glutathione with conjugated carbonyls. Z. Naturforsch., 1975, 30, 466-473.
123. Witz, G. Biological interactions of alpha, beta-unsaturated aldehyde. Free Radic. Biol. Med., 1989, 7, 333-349.
124. Gan, J. C.; Ansari, G. A. S. Plausible mechanism of inactivation of plasma alpha-1-proteinase inhibitor by acrolein. Res. Comm. Chem. Pathol. Pharmacol., 1987, 55, 419-422.
125. Chung, F. L.; Young, R; Hecht, S. S. Formation of cyclic 1, N2-propanodeoxyquanosine adducts in DNA upon with acrolein or crotonaldehyde. Cancer Res. 1984, 44, 990-995.
126. Gutteridge, J. C. M. Lipid peroxidation and antioxidants as biomarkers of tissue damage. Clin. Chem., 1996, 41, 1819-1828.
127. Bovens, A.; Oshino, N.; Chance, B. The cellular production of hydrogen peroxide. Biochem. J., 1972, 128, 612-630.
128. Oudijk, E. J.; Gerritsen, W. B.; Nijhuis, E. H.; Kanters, D.; Maesen, B. L.; Lammers, J. W.; Koenderman, L. Expression of primingassociated cellular markers on neutrophils during anexacerbation of COPD. Respir. Med., 2006, 100, 1791-1799.
129. Nowak, D.; Kasielski, M.; Antczak, A.; Pietras, T.; Bialasiewicz, P. Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir. Med., 1999, 93, 389-396.
130. Kasielski, M.; Nowak, D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir. Med., 2001, 95, 448-456.
131. Schleiss, M. B.; Holz, O.; Behnke, M.; Richter, K.; Magnussen, H.; Jörres, R. A. The concentration of hydrogen peroxide in exhaled air depends on expiratory flow rate. Eur. Respir. J., 2000, 16, 1115-1118.
132. Gajdocsi, R.; Bikov, A.; Antus, B.; Horvath, I.; Barnes, P. J.; Kharitonov, S. A. Assessment of reproducibility of exhaled hydrogen peroxide concentration and the effect of breathing pattern in healthy subjects. J. Aerosol. Med. Pulm. Drug Deliv., 2011, 24, 271-275.
133. Ricciardolo, F. L.; Di Stefano, A.; Sabatini, F.; Folkerts, G. Reactive nitrogen species in the respiratory tract. Eur. J. Pharmacol., 2006, 533, 240-252.
134. Gaston, B.; Drazen, J. M.; Loscalzo, J.; Stamler, J. S. The biology of nitrogen oxides in the airways. Am. J. Respir. Crit. Care Med., 1994, 149, 538-551.
135. Corradi, M.; Montuschi, P.; Donnelly, L. E.; Pesci, A.; Kharitonov, S. A.; Barnes, P. J. Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. Am. J. Respir. Crit. Care Med., 2001, 163, 854-858.
136. Ricciardolo, F. L.; Caramori, G.; Ito, K.; Capelli, A.; Brun, P.; Abatangelo, G.; Papi, A.; Chung, K. F.; Adcock, I.; Barnes, P. J.; Donner, C. F.; Rossi, A.; Di Stefano, A. Nitrosative stress in the bronchial mucosa of severe chronic obstructive pulmonary disease. J. Allergy Clin. Immunol., 2005, 116, 1028-1035.
137. Sugiura, H.; Ichinose, M.; Tomaki, M.; Ogawa, H.; Koarai, A.; Kitamuro, T.; Komaki, Y.; Akita, T.; Nishino, H.; Okamoto, S.; Akaike, T.; Hattori, T. Quantitative assessment of protein-bound tyrosine nitration in airway secretions from patients with inflammatory airway disease. Free. Radic. Res., 2004, 38, 49-57.
138. Ricciardolo, F. L.; Rado, V.; Fabbri, L. M.; Sterk, P. J.; Di Maria, G. U.; Geppetti, P. Bronchoconstriction induced by citric acid inhalation in guinea pigs: role of tachykinins, bradykinin, and nitric oxide. Am. J. Respir. Crit. Care Med., 1999, 159, 557-562.
139. Clary-Meinesz, C.; Mouroux, J.; Cosson, J.; Huitorel, P.; Blaive, B. Influence of external pH on ciliary beat frequency in human bronchi and bronchioles. Eur. Respir. J., 1998, 11, 330-333.
140. Hunt, J. F.; Fang, K.; Malik, R.; Snyder, A.; Malhotra, N.; Platts-Mills, T. A.; Gaston, B. Endogenous airway acidification. Implications for asthma pathophysiology. Am. J. Respir. Crit. Care Med., 2000, 161, 694-699.
141. Kostikas, K.; Papatheodorou, G.; Ganas, K.; Psathakis, K.; Panagou, P.; Loukides, S. pH in expired breath condensate of patients with inflammatory airway diseases. Am. J. Respir. Crit. Care Med., 2002, 165, 1364-1370.
142. Borrill, Z.; Starkey, C.; Vestbo, J.; Singh, D. Reproducibility of exhaled breath condensate pH in chronic obstructive pulmonary disease. Eur. Respir. J., 2005, 25, 269-274.
143. Tate, S.; MacGregor, G.; Davis, M.; Innes, J. A.; Greening, A. P. Airways in cystic fibrosis are acidified: detection by exhaled breath condensate. Thorax, 2002, 57, 926-929.
144. Ojoo, J. C.; Mulrennan, S. A.; Kastelik, J. A.; Morice, A. H.; Redington, A. E. Exhaled breath condensate pH and exhaled nitric oxide in allergic asthma and in cystic fibrosis. Thorax, 2005, 60, 22-26.
145. MacGregor, G.; Ellis, S.; Andrews, J.; Imrie, M.; Innes, A.; Greening, A. P.; Cunningham, S. Breath condensate ammonium is lower in children with chronic asthma. Eur. Respir. J., 2005, 26, 271-276.
146. Koczulla, R.; Dragonieri, S.; Schot, R.; Bals, R.; Gauw, S. A.; Vogelmeier, C.; Rabe, K. F.; Sterk, P. J.; Hiemstra, P. S. Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients. Respir. Res., 2009, 10, 78.
147. Nicolaou, N. C.; Lowe, L. A.; Murray, C. S.; Woodcock, A.; Simpson, A.; Custovic, A. Exhaled breath condensate pH and childhood asthma: unselected birth cohort study. Am. J. Respir. Crit. Care Med., 2006, 174, 254-259.
148. Vaughan, J.; Ngamtrakulpanit, L.; Pajewski, T. N.; Turner, R.; Nguyen, T. A.; Smith, A.; Urban, P.; Hom, S.; Gaston, B.; Hunt, J. Exhaled breath condensate pH is a robust and reproducible assay of airway acidity. Eur. Respir. J., 2003, 22, 889-894.
149. Kullmann, T.; Barta, I.; Lazar, Z.; Szili, B.; Barat, E.; Valyon, M.; Horvath I. Exhaled breath condensate pH standardised for CO2 partial pressure. Eur. Respir. J., 2007, 29, 496-501.
150. Antus, B.; Barta, I.; Kullmann, T.; Lazar, Z.; Valyon, M.; Horvath, I.; Csiszer, E. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: A longitudinal study. Am. J. Respir. Crit. Care Med., 2010, 182, 1492-1497.
151. Antus, B.; Barta, I.; Csiszer, E.; Kelemen, K. Exhaled breath condensate pH in patients with cystic fibrosis. Inflamm. Res., 2012, 61, 1141-1147.
152. Antus, B.; Barta, I. Exhaled breath condensate pH in patients with lung cancer. Lung Cancer, 2012, 75, 178-180.
153. Soter, S.; Kelemen, K.; Barta, I.; Valyon, M.; Csiszer, E.; Antus, B. Exhaled breath condensate pH in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation, 2011, 91, 793-797.
154. Kullmann, T.; Barta, I.; Antus, B.; Horvath, I. Drinking influences exhaled breath condensate acidity. Lung, 2008, 186, 263-268.
155. Effros, R. M.; Casaburi, R.; Su, J.; Dunning, M.; Torday, J.; Biller, J.; Shaker, R. The effects of volatile salivary acids and bases on exhaled breath condensate pH. Am. J. Respir. Crit. Care Med., 2006, 173, 386-392.
156. Wells, K.; Vaughan, J.; Pajewski, T. N.; Hom, S.; Ngamtrakulpanit, L.; Smith, A.; Nguyen, A.; Turner, R.; Hunt, J. Exhaled breath condensate pH assays are not influenced by oral ammonia. Thorax, 2005, 60, 27-31.